-
Jan 15, 2025 | 
onclive.com | Heather Wakelee |Jacob Sands
OpinionVideoJanuary 15, 2025Author(s):,Panelists discuss the unmet needs and future perspectives in the treatment of RET-positive non–small cell lung cancer (NSCLC), focusing on areas for improvement in therapy and the potential for new treatment strategies. Dr. Wakelee: Thank you to Dr Sands for this insightful discussion. Before we end, I would like to get some closing thoughts from Dr Sands on unmet needs and future perspectives on the treatment of RET fusion-positive NSCLC.
-
Jan 15, 2025 | 
onclive.com | Heather Wakelee |Jacob Sands
OpinionVideoJanuary 15, 2025Author(s):,Panelists discuss how to monitor patients for response to treatment and early signs of resistance in RET fusion–positive non–small cell lung cancer (NSCLC), including the approach to follow-up molecular testing, and describe strategies for treatment sequencing after disease progression on RET inhibitors. Dr Sands to Dr Wakelee: How do you monitor patients for response to treatment and early signs of resistance?
-
Jan 8, 2025 | 
onclive.com | Heather Wakelee |Jacob Sands
OpinionVideoJanuary 8, 2025Author(s):,Panelists discuss the common adverse effects for patients receiving selpercatinib or pralsetinib, strategies for managing these effects, and whether differences in the safety profiles of these drugs influence treatment choices for RET fusion–positive non–small cell lung cancer. Dr Wakelee to Dr Sands: What adverse effects are common for patients receiving selpercatinib or pralsetinib? How do you manage these adverse effects?
-
Jan 8, 2025 | 
onclive.com | Heather Wakelee |Jacob Sands
OpinionVideoJanuary 8, 2025Author(s):,Panelists discuss the situations in which other first-line therapies, such as cabozantinib or PD-L1–positive chemotherapy options, might be considered for RET fusion–positive non–small cell lung cancer (NSCLC), and compare the role of chemotherapy and immunotherapy to that of RET inhibitors in this setting. Dr Sands to Dr Wakelee: In what situations do you consider other first-line therapies (eg, cabozantinib, PD-L1–positive chemotherapy options)?
-
Dec 10, 2024 | 
onclive.com | Heather Wakelee |Jacob Sands
-
Oct 9, 2024 | 
nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more
AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.
-
Nov 13, 2023 | 
onclive.com | Heather Wakelee
Heather Wakelee, MD, FASCO, professor, medicine, chief, Division of Oncology, Stanford University School of Medicine, deputy director, division chief, Medical Oncology, Stanford Cancer Institute, president, International Association for the Study of Lung Cancer, discusses the significance of early data on the use of taletrectinib (AB-106) in patients with ROS1-positive non–small cell lung cancer (NSCLC) from the phase 2 TRUST-II trial (NCT04919811).
-
Oct 9, 2023 | 
targetedonc.com | Heather Wakelee
Heather Wakelee, MD, from Stanford University School of Medicine and the Stanford Cancer Institute, discusses the efficacy findings from the phase 3 KEYNOTE-671 clinical trial (NCT03425643) evaluating the addition of pembrolizumab (Keytruda) to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone for patients with early-stage non–small cell lung cancer (NSCLC).
-
Sep 13, 2023 | 
onclive.com | Edward Kim |Heather Wakelee |Karen L. Reckamp |Edgardo S. Santos |Lyudmila A Bazhenova
During the 2023 International Lung Cancer Congress, OncLive® asked experts from the lung cancer field to discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices. These experts included:Karen L.
-
Aug 15, 2023 | 
obroncology.com | Heather Wakelee |Robert A. Figlin
The World Conference on Lung Cancer (World Lung) will be held in Singapore, September 9–12. The current president of International Association for the Study of Lung Cancer (IASLC), Heather A. Wakelee, MD, division chief of medical oncology at the Stanford Cancer Institute in California, shares which presentations and findings she is most looking forward to at this year’s event.
